Lexicon Pharma (LXRX) Reports Q4 EPS of $0.76
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.42 -4.05%
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.76, versus ($0.03) reported last year. Revenue for the quarter came in at $127.3 million, versus $21.5 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- University Bancorp acquires remaining 20% of UIF for $15.2M
- New Break Resources plans $550,000 flow-through share offering
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
